Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine

References

• Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–1300. doi: 10.1016/S0140-6736(17)33293-2
   PubMed Web of Science ®Google Scholar
• Palese P. Orthomyxoviridae. Virology. 2007. 1647–1740.
   Google Scholar
• Palese P, Tumpey TM, Garcia-Sastre A. What can we learn from reconstructing the extinct 1918 pandemic influenza virus? Immunity. 2006;24(2):121–124. doi: 10.1016/j.immuni.2006.01.007
   PubMed Web of Science ®Google Scholar
• Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018 Jun 28;4(1):3. doi: 10.1038/s41572-018-0002-y
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Thompson MG, Blanton L, et al. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine. 2021;39(28):3678–3695. doi: 10.1016/j.vaccine.2021.05.011
   PubMed Web of Science ®Google Scholar
• Olson SM, Newhams MM, Halasa NB, et al. Vaccine effectiveness against life-threatening influenza illness in US children. Clin Infect Dis. 2022 Aug 25;75(2):230–238. doi: 10.1093/cid/ciab931
   PubMed Web of Science ®Google Scholar
• FDA. Common ingredients in U.S. Licensed vaccines. 2019. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/common-ingredients-us-licensed-vaccines.
   Google Scholar
• Information for the 2023-2024 flu season 2024. 2024 Jan 16 [cited 2024 Feb 25]. Available from: https://www.cdc.gov/flu/season/faq-flu-season-2023-2024.htm
   Google Scholar
• Li Y-T, Linster M, Mendenhall IH, et al. Avian influenza viruses in humans: lessons from past outbreaks. Br Med Bull. 2019;132(1):81–95. doi: 10.1093/bmb/ldz036
   PubMed Web of Science ®Google Scholar
• Bolton MJ, Ort JT, McBride R, et al. Antigenic and virological properties of an H3N2 variant that will likely dominate the 2021-2022 northern hemisphere influenza season. medRxiv. 2021:2021.12. 15.21267857.
   Google Scholar
• Francis T, Salk JE, Pearson HE, et al. Protective effect of vaccination against induced influenza a 1. J Clin Investig. 1945;24(4):536–546. doi: 10.1172/JCI101633
   PubMed Web of Science ®Google Scholar
• Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12(9):1085–1094.
   PubMed Web of Science ®Google Scholar
• Burnet F. Growth of influenza virus in the allantoic cavity of the chick embryo. Aust J Exp Biol Med Sci. 1941;19(4):291–295. doi: 10.1038/icb.1941.44
   Google Scholar
• Beyer W, Palache A, Osterhaus A. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines. Clin Drug Investig. 1998;15(1):1–12. doi: 10.2165/00044011-199815010-00001
   PubMed Web of Science ®Google Scholar
• Allen JD, Ray S, Ross TM. Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses. PLoS One. 2018;13(9):e0204284.
   PubMed Web of Science ®Google Scholar
• Kim YH, Hong KJ, Kim H, et al. Influenza vaccines: Past, present, and future. Rev Med Virol. 2022;32(1):e2243. doi: 10.1002/rmv.2243
   PubMed Web of Science ®Google Scholar
• Midthun KMS. CBER approval letter, influenza virus vaccine, live, intranasal (FluMist). 2003. Available from: https://web.archive.org/web/20070929154324/https://www.fda.gov/cber/approvltr/inflmed061703L.htm
   Google Scholar
• Cox MM, Izikson R, Post P, et al. Safety, efficacy, and immunogenicity of flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines. 2015 Jul;3(4):97–108.
   PubMedGoogle Scholar
• Zhao F, Liu L, Xu M, et al. Assessments of different inactivating reagents in formulating transmissible gastroenteritis virus vaccine. Virol J. 2020;17(1):1–9. doi: 10.1186/s12985-020-01433-8
   PubMed Web of Science ®Google Scholar
• Sanders B, Koldijk M, Schuitemaker H. Inactivated viral vaccines. Vaccine analysis: strategies. Principles Control. 2014;45–80.
   Google Scholar
• Delrue I, Verzele D, Madder A, et al. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert review of vaccines. Expert Rev Vaccines. 2012;11(6):695–719. doi: 10.1586/erv.12.38
   PubMed Web of Science ®Google Scholar
• Perrin P, Morgeaux S. Inactivation of DNA by β-propiolactone. Biologicals. 1995;23(3):207–211. doi: 10.1006/biol.1995.0034
   PubMed Web of Science ®Google Scholar
• Craig A. IARC monographs on the evaluation of carcinogenic risk of chemicals to man. Br J Cancer. 1973;27(2):190. doi: 10.1038/bjc.1973.23
   Google Scholar
• Park J, Fong Legaspi SL, Schwartzman LM, et al. An inactivated multivalent influenza a virus vaccine is broadly protective in mice and ferrets. Sci Trans Med. 2022;14(653):eabo2167. doi: 10.1126/scitranslmed.abo2167
   PubMed Web of Science ®Google Scholar
• Španinger E, Bren U. Carcinogenesis of β-propiolactone: a computational study. Chem Res Toxicol. 2020 Mar 16;33(3):769–781.
   PubMed Web of Science ®Google Scholar
• Uittenbogaard JP, Zomer B, Hoogerhout P, et al. Reactions of β-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses. J Biol Chem. 2011;286(42):36198–36214. doi: 10.1074/jbc.M111.279232
   PubMed Web of Science ®Google Scholar
• Herrera-Rodriguez J, Signorazzi A, Holtrop M, et al. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production. Vaccine. 2019 Mar 14;37(12):1630–1637. doi: 10.1016/j.vaccine.2019.01.086
   PubMed Web of Science ®Google Scholar
• Elveborg S, Monteil VM, Mirazimi A. Methods of inactivation of highly pathogenic viruses for molecular, serology or vaccine development purposes. Pathogens. 2022;11(2):271. doi: 10.3390/pathogens11020271
   PubMed Web of Science ®Google Scholar
• Budimir N, Huckriede A, Meijerhof T, et al. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One. 2012;7(1):e30898. doi: 10.1371/journal.pone.0030898
   PubMed Web of Science ®Google Scholar
• Gupta D, Parthasarathy H, Sah V, et al. Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential. Virus res. 2021 Nov 01;305:198555.
   PubMed Web of Science ®Google Scholar
• Budowsky E, Friedman E, Zheleznova N, et al. Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of β-propiolactone. Vaccine. 1991;9(6):398–402. doi: 10.1016/0264-410X(91)90125-P
   PubMed Web of Science ®Google Scholar
• Pawar SD, Murtadak VB, Kale SD, et al. Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation. J Virol Methods. 2015;222:28–33. doi: 10.1016/j.jviromet.2015.05.004
   PubMed Web of Science ®Google Scholar
• Chen J-R, Liu Y-M, Tseng Y-C, et al. Better influenza vaccines: an industry perspective. J Biomed Sci. 2020;27(1):1–11. doi: 10.1186/s12929-020-0626-6
   PubMed Web of Science ®Google Scholar
• Parkman PD, Hopps HE, Rastogi SC, et al. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis. 1977;136(Supplement_3):S722–S730. doi: 10.1093/infdis/136.Supplement_3.S722
   PubMedGoogle Scholar
• Huang X, Fan T, Li L, et al. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial. Human Vaccines Immunother. 2022;18(5):2079924. doi: 10.1080/21645515.2022.2079924
   PubMed Web of Science ®Google Scholar
• Soema PC, Kompier R, Amorij J-P, et al. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251–263. doi: 10.1016/j.ejpb.2015.05.023
   PubMed Web of Science ®Google Scholar
• Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singapore. 2008;37(6):510. doi: 10.47102/annals-acadmedsg.V37N6p510
   PubMed Web of Science ®Google Scholar
• Lupulescu E, Ioniţă E, Botez D, et al. An immunogenicity and reactogenicity study of a purified, inactivated trivalent influenza vaccine for parenteral administration prepared for the 1996-1997 season. Bacteriol Virusol Parazitol Epidemiol (Bucharest, Romania: 1990). 1997;42(1–2):110–112.
   PubMedGoogle Scholar
• Kon TC, Onu A, Berbecila L, et al. Influenza vaccine manufacturing: effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS One. 2016;11(3):e0150700–e0150700. doi: 10.1371/journal.pone.0150700
   PubMed Web of Science ®Google Scholar
• Robertson CA, Mercer M, Selmani A, et al. Safety and immunogenicity of a full-dose, split-virion, inactivated, quadrivalent influenza vaccine in healthy children 6-35 months of age: a randomized controlled clinical trial. Pediatr Infect Dis J. 2019 Mar;38(3):323–328.
   PubMed Web of Science ®Google Scholar
• Sarsenbayeva G, Issagulov T, Kassenov M, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan. Human Vaccines Immunother. 2020;16(8):1791–1797. doi: 10.1080/21645515.2019.1705691
   PubMed Web of Science ®Google Scholar
• Shingai M, Nomura N, Sekiya T, et al. Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells. Vaccine. 2021;39(29):3940–3951. doi: 10.1016/j.vaccine.2021.05.065
   PubMed Web of Science ®Google Scholar
• Geeraedts F, Bungener L, Pool J, et al. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza and other respiratory viruses. Influenza Other Respir Viruses. 2008;2(2):41–51. doi: 10.1111/j.1750-2659.2008.00038.x
   PubMed Web of Science ®Google Scholar
• O’Gorman WE, Huang H, Wei Y-L, et al. The split virus influenza vaccine rapidly activates immune cells through Fcγ receptors. Vaccine. 2014 Oct 14;32(45):5989–5997. doi: 10.1016/j.vaccine.2014.07.115
   PubMed Web of Science ®Google Scholar
• Handabile C, Sekiya T, Nomura N, et al. Inactivated whole virus particle influenza vaccine induces anti-neuraminidase antibodies that May contribute to cross-protection against heterologous virus infection. Vaccines. 2022;10(5):804. doi: 10.3390/vaccines10050804
   Web of Science ®Google Scholar
• Ni Y, Guo J, Turner D, et al. An improved inactivated influenza vaccine with enhanced cross protection. Front Immunol. 2018;9:1815. doi: 10.3389/fimmu.2018.01815
   PubMed Web of Science ®Google Scholar
• Rajaram S, Boikos C, Gelone DK, et al. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Therapeutic advances in vaccines and immunotherapy. Ther Adv Vaccines Immunother. 2020;8:2515135520908121. doi: 10.1177/2515135520908121
   Google Scholar
• Merten O-W, Hannoun C, Manuguerra J-C, et al. Production of influenza virus in cell cultures for vaccine preparation. Novel Strat The Design Prod Vac. 1996;141–151.
   Google Scholar
• Lamb YN. Cell-based quadrivalent inactivated influenza virus vaccine (Flucelvax® Tetra/Flucelvax Quadrivalent®): a review in the prevention of influenza. Drugs. 2019;79(12):1337–1348. doi: 10.1007/s40265-019-01176-z
   PubMed Web of Science ®Google Scholar
• Yu ED, Grifoni A, Sutherland A, et al. Balanced cellular and humoral immune responses targeting multiple antigens in adults receiving a quadrivalent inactivated influenza vaccine. Vaccines. 2021;9(5):426. doi: 10.3390/vaccines9050426
   Web of Science ®Google Scholar
• Garcia-Sastre A, Palese P. Genetic manipulation of negative-strand RNA virus genomes. Annu Rev Microbiol. 1993;47(1):765–790. doi: 10.1146/annurev.mi.47.100193.004001
   PubMedGoogle Scholar
• Neumann G, Watanabe T, Ito H, et al. Generation of influenza a viruses entirely from cloned cDnas. Proc Nat Acad Sci. 1999;96(16):9345–9350. doi: 10.1073/pnas.96.16.9345
   PubMed Web of Science ®Google Scholar
• Hoffmann E, Neumann G, Kawaoka Y, et al. A DNA transfection system for generation of influenza a virus from eight plasmids. Proc Nat Acad Sci. 2000;97(11):6108–6113. doi: 10.1073/pnas.100133697
   PubMed Web of Science ®Google Scholar
• Krammer F. The human antibody response to influenza a virus infection and vaccination. Nat Rev Immunol. 2019;19(6):383–397. doi: 10.1038/s41577-019-0143-6
   PubMed Web of Science ®Google Scholar
• Kirkpatrick E, Qiu X, Wilson PC, et al. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci Rep. 2018;8(1):1–14. doi: 10.1038/s41598-018-28706-1
   PubMedGoogle Scholar
• Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013;3(5):521–530. doi: 10.1016/j.coviro.2013.07.007
   PubMed Web of Science ®Google Scholar
• Gomez Lorenzo MM, Fenton MJ. Immunobiology of Influenza Vaccines. Chest. 2013 Feb 01;143(2):502–510.
   PubMed Web of Science ®Google Scholar
• Thornlow DN, Macintyre AN, Oguin TH 3rd, et al. Altering the immunogenicity of hemagglutinin immunogens by hyperglycosylation and disulfide stabilization. Front Immunol. 2021;12:737973. doi: 10.3389/fimmu.2021.737973
   PubMed Web of Science ®Google Scholar
• Lin S-C, Liu W-C, Jan J-T, et al. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One. 2014;9(3):e92822. doi: 10.1371/journal.pone.0092822
   PubMed Web of Science ®Google Scholar
• Impagliazzo A, Milder F, Kuipers H, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015;349(6254):1301–1306. doi: 10.1126/science.aac7263
   PubMed Web of Science ®Google Scholar
• Darricarrère N, Qiu Y, Kanekiyo M, et al. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Sci, trans med. 2021;13(583):eabe5449. doi: 10.1126/scitranslmed.abe5449
   PubMed Web of Science ®Google Scholar
• Krammer F, Pica N, Hai R, et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013;87(12):6542–6550. doi: 10.1128/JVI.00641-13
   PubMed Web of Science ®Google Scholar
• Sun W, Kirkpatrick E, Ermler M, et al. Development of influenza B universal vaccine candidates using the “mosaic” hemagglutinin approach. J Virol. 2019;93(12): doi: 10.1128/JVI.00333-19
   Web of Science ®Google Scholar
• Schneemann A, Speir JA, Tan GS, et al. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol. 2012;86(21):11686–11697. doi: 10.1128/JVI.01694-12
   PubMed Web of Science ®Google Scholar
• Liu X, Zhao T, Wang L, et al. A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses. NPJ Vaccin. 2023;8(1):132. doi: 10.1038/s41541-023-00728-5
   PubMed Web of Science ®Google Scholar
• Liao H-Y, Wang S-C, Ko Y-A, et al. Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes. Proc Nat Acad Sci. 2020;117(30):17757–17763. doi: 10.1073/pnas.2004783117
   PubMed Web of Science ®Google Scholar
• Liu Y, Strohmeier S, González-Domínguez I, et al. Mosaic hemagglutinin-based whole inactivated virus vaccines induce broad protection against influenza B virus challenge in mice [original research]. Front Immunol. 2021 Sep 16;12:12.
   Web of Science ®Google Scholar
• Choi A, Bouzya B, Cortés Franco K-D, et al. Chimeric hemagglutinin-based influenza virus vaccines induce protective stalk-specific humoral immunity and cellular responses in mice. Immunohorizons. 2019;3(4):133–148. doi: 10.4049/immunohorizons.1900022
   PubMedGoogle Scholar
• Nachbagauer R, Feser J, Naficy A, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Med. 2021 Jan 01;27(1):106–114. doi: 10.1038/s41591-020-1118-7
   PubMed Web of Science ®Google Scholar
• Andrews SF, Huang Y, Kaur K, et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med. 2015 Dec 2;7(316):316ra192. doi: 10.1126/scitranslmed.aad0522
   PubMed Web of Science ®Google Scholar
• Chen M-W, Cheng T-J, Huang Y, et al. A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA. 2008;105(36):13538–13543. doi: 10.1073/pnas.0806901105
   PubMed Web of Science ®Google Scholar
• Webby RJ, Weaver EA, Miyaji EN. Centralized consensus hemagglutinin genes induce protective immunity against H1, H3 and H5 influenza viruses. PLoS One. 2015;10(10):e0140702.
   PubMed Web of Science ®Google Scholar
• Petro-Turnquist EM, Bullard BL, Pekarek MJ, et al. Adenoviral-vectored centralized consensus hemagglutinin vaccine provides broad protection against H2 influenza a virus. Vaccines. 2022;10(6):926. doi: 10.3390/vaccines10060926
   Web of Science ®Google Scholar
• Huang Y, França MS, Allen JD, et al. Next generation of computationally optimized broadly reactive HA vaccines elicited cross-reactive immune responses and provided protection against H1N1 virus infection. Vaccines. 2021;9(7):793. doi: 10.3390/vaccines9070793
   PubMed Web of Science ®Google Scholar
• Allen JD. Design and characterization of computationally optimized broadly reactive antigen (cobra) vaccines against human seasonal influenza a (H3N2). Viruses: University of Georgia; 2021.
   Google Scholar
• Yu J, Sreenivasan C, Sheng Z, et al. A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses. Vaccine. 2023;41(42):6318–6326. doi: 10.1016/j.vaccine.2023.09.007
   PubMed Web of Science ®Google Scholar
• Krammer F, Fouchier RA, Eichelberger MC, et al. Naction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? MBio. 2018;9(2):10–1128. doi: 10.1128/mBio.02332-17
   Web of Science ®Google Scholar
• Essink B, Fierro C, Rosen J, et al. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine. 2020;38(2):242–250. doi: 10.1016/j.vaccine.2019.10.021
   PubMed Web of Science ®Google Scholar
• Coleman BL, Sanderson R, Haag MD, et al. Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis. Influenza Resp Viruses. 2021;15(6):813–823. doi: 10.1111/irv.12871
   PubMed Web of Science ®Google Scholar
• Zhu W, Dong C, Wei L, et al. Promising adjuvants and platforms for influenza vaccine development. Pharmaceutics. 2021;13(1):68. doi: 10.3390/pharmaceutics13010068
   PubMed Web of Science ®Google Scholar
• Cole SL, Cybulski VA, Whitacre M, et al. Influenza vaccines using liposomal formulations of toll-like receptor (TLR) 7/8 and 4 agonists as adjuvants. J Immunol. 2020;204(1_Supplement):.245.12–.245.12. doi: 10.4049/jimmunol.204.Supp.245.12
   Web of Science ®Google Scholar
• Kaushik D, Dhingra S, Patil MT, et al. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant. Human Vaccines Immunother. 2020;16(8):1989–1996. doi: 10.1080/21645515.2019.1710409
   PubMed Web of Science ®Google Scholar
• Goff PH, Hayashi T, Martínez-Gil L, et al. Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol. 2015;89(6):3221–3235. doi: 10.1128/JVI.03337-14
   PubMed Web of Science ®Google Scholar
• Moriyama M, Koshiba T, Ichinohe T. Influenza A virus M2 protein triggers mitochondrial DNA-mediated antiviral immune responses. Nat Commun. 2019;10(1):4624. doi: 10.1038/s41467-019-12632-5
   PubMed Web of Science ®Google Scholar
• Ritchie C, Li L. cGAMP as an adjuvant in antiviral vaccines and cancer immunotherapy. Biochemistry. 2020;59(18):1713–1715. doi: 10.1021/acs.biochem.0c00226
   PubMed Web of Science ®Google Scholar
• Vassilieva EV, Taylor DW, Compans RW. Combination of STING pathway agonist with saponin is an effective adjuvant in immunosenescent mice. Front Immunol. 2019;10:3006. doi: 10.3389/fimmu.2019.03006
   PubMed Web of Science ®Google Scholar
• Isakova-Sivak I, Stepanova E, Mezhenskaya D, et al. Influenza vaccine: Progress in a vaccine that elicits a broad immune response. Expert Rev Vaccines. 2021;20(9):1097–1112. doi: 10.1080/14760584.2021.1964961
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Lau HMP, Sloane H, et al. Homologous peptides derived from influenza A, B and C viruses induce variable CD8 + T cell responses with cross-reactive potential. Clin Trans Imm. 2022;11(10):e1422. doi: 10.1002/cti2.1422
   PubMed Web of Science ®Google Scholar
• Wood LV, Gandhapudi SK, Sundarapandiyan K, et al. R-DOTAP (versamune): a novel enantiospecific cationic lipid nanoparticle that induces CD4 and CD8 cellular immune responses to whole protein and tumor-specific peptide antigens. Am Soc Clin Oncol. 2020;38(15_suppl):e15211–e15211. doi: 10.1200/JCO.2020.38.15_suppl.e15211
   Web of Science ®Google Scholar
• Gandhapudi SK, Shi H, Ward MR, et al. Recombinant protein vaccines formulated with enantio-specific cationic lipid R-DOTAP induce protective cellular and antibody-mediated immune responses in mice. Viruses. 2023;15(2):432. doi: 10.3390/v15020432
   PubMed Web of Science ®Google Scholar
• Flu. The history of influenza 2023. Available from: https://www.flu.com/Articles/2022/The-History-of-Influenza
   Google Scholar